Rectal Neuroendocrine Tumor with Concomitant Erdheim-Chester Disease: A Rare Case Report Abstract #2938

Introduction: Rectal neuroendocrine tumor (NET), a type of rare tumor, is rather rarer when accompanied by non-Langerhans cells histiocytosis named Erdheim-Chester disease (ECD).
Aim(s): To report a patient suffered from rectal NET and ECD simultaneously.
Materials and methods: A 44-year-old man, with a 7 years history of rectal NET, complaining that he has had a backache as well as vision and hearing impairment for 2 years. Craniocerebral MRI revealed thickened bilateral choroid plexus and endocranium with multiple nodules. Pelvic MRI identified abnormal signals of lumbar, bilateral pelvis and proximal femurs. Both 18F-FDG-PET/CT and 68Ga-DOTANOC-PET/CT demonstrated high uptake of radiotracers in the region of perirectal lymph nodes while no uptake in the lesions of bones and brain. After multidisciplinary discussion, pelvic bones biopsy was performed to identify the property of lesions. Notably, histology reveled infiltration of abundant foamy histiocytes. Immunohistochemistry confirmed CD68(+), CD163(+), Factor XIII a (+), S-100(-), CD1a (-), Langerin (-). And there was no mutation of BRAF V600E. So, the final diagnosis was ECD. For treatment of ECD, interferon alfa (180µg/week) was applied to the patient. To remove lymph node metastasis of rectal NET, a total mesorectal excision surgery was performed.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Professor Jie Chen

To read results and conclusion, please login ...

Further abstracts you may be interested in

#57 Clinical and demographic characteristics in patients newly diagnosed with neuroendocrine tumors (NET)
Introduction: Neuroendocrine tumors (NETs) are tumors that form from cells that release hormones in response to a signal from the nervous system. These tumors may secrete higher-than-normal amounts of hormones, which can cause many different symptoms.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Chi-Chang Chen
#88 EpCam expression and detection of circulating tumor cells in neuroendocrine tumors
Introduction: Using the CellSearchTM system, circulating tumor cells (CTCs) can be reproducibly enumerated according to expression of EpCAM and cytokeratins 8, 18 or 19 and the absence of the haemopoietic marker CD45. The number of CTCs detected in 7.5 mls blood has been shown to correlate with prognosis in breast, colon and prostate cancer and can predict response to therapy. Neuroendocrine tumors (NETs) have not previously been reported to express EpCAM and have not been systematically assessed for presence of CTCs. We have therefore explored the expression of EpCAM in NETs and the detection of NET cells in the circulation.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#158 Progression-free survival (PFS) as a primary endpoint for clinical studies in advanced neuroendocrine tumors (NETs)
Introduction: Successfully testing new antitumor agents requires primary study endpoints that are clinically important, and also provide sufficient statistical power within a timeframe and population size that is feasible for the tumor type. Using overall survival (OS) as the primary endpoint in NET studies is challenging because of the low incidence (5.25/100,000 annually), disease heterogeneity, extended survival time (Yao 2008), and confounding effects of multiple therapies. These inherent aspects of NETs make OS an extremely difficult and challenging endpoint to evaluate clinical efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Simron Singh
Authors: Singh S, Law C, ...
#259 Risk of Cardiovascular Events (CV) in Patients Newly Diagnosed with Neuroendocrine Tumors (NET)
Introduction: NETs are malignant neoplasms capable of systemic hormone production. Oversecretion of hormones can result in many different symptoms, including CV events such as CAD, valvular disease and stroke.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Chi-Chang Chen
Authors: Chen C C, Liu Z M, Hess G P, Yao J C, ...
#260 Risk of Hepatic and Gastrointestinal (GI) Events in Patients Newly Diagnosed with Neuroendocrine Tumors (NET)
Introduction: NET derives from peptide- and hormone-producing cells scattered throughout the body. In excess, these can lead to many clinical manifestations, including GI events (ex. enteritis, and liver disease).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Chi-Chang Chen
Authors: Hess G P, Liu Z M, Chen C C, Yao J C, ...